Bharat Biotech Covaxin

Hyderabad: Bharat Biotech on Monday announced that it has commenced export of Covid-19 vaccine Covaxin. Long Pending export orders have been executed during November, to be further expanded during the following months, the…
Read More...

New Delhi: The Hyderabad-based vaccine manufacturer Bharat Biotech on Thursday said that the recent study on Covaxin provides 'evidence for effectiveness' of India's first indigenous vaccine against Covid-19. Reacting to a real-world…
Read More...

New Delhi: A single-dose of Covaxin provides a similar immunity response in previously Covid-infected people as those without previous history of Covid infection with two doses of vaccine, says Indian Council of Medical Research's latest…
Read More...

Bhubaneswar: The founder and chairman of Bharat Biotech Krishna Ella visited Bhubaneswar on Wednesday and informed that the Covid-19 vaccine production will start in Odisha by June 2022. The vaccine production unit will be set up on the…
Read More...

New Delhi: The trials of Bharat Biotech's covid-19 vaccine, Covaxin, on children are underway. The results are expected by September, said AIIMS director Randeep Guleria. According to sources, the second dose of Covaxin trials is likely…
Read More...

New Delhi: Bharat Biotech concluded the final analysis of its Covid-19 vaccine Covaxin and announced the safety and efficacy analysis data from Phase 3 clinical trials on Saturday. According to the analysis, Covaxin has been found to be…
Read More...

New Delhi: Brazil has decided to suspend a USD 324 million contract to buy 20 million doses of Bharat Biotech’s Covaxin vaccine amid a probe into accusations of irregularities against President Jair Bolsonaro. The head of the Federal…
Read More...

New Delhi: The Union Health Ministry categorised the Delta Plus variant of the novel coronavirus as a ‘variant of concern’. Delta variant has mutated into Delta Plus which is said to be highly infectious. According to sources, India…
Read More...

New Delhi: Amid concerns over the effectiveness of Covid vaccines, the Hyderabad-based Bharat Biotech has submitted phase III trial data of Covaxin to Drugs Controller General of India (DCGI). Phase-III trial data is also required for…
Read More...

New Delhi: The supply price of Covaxin to the government of India at Rs 150 a dose is a non-competitive price and clearly not sustainable in the long run. Hence a higher price in private markets is required to offset part of the costs,…
Read More...